» Articles » PMID: 16822319

Papillary Microcarcinomas of the Thyroid Gland and Immunohistochemical Analysis of Expression of P53 Protein in Papillary Microcarcinomas

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2006 Jul 11
PMID 16822319
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Thyroid papillary microcarcinoma (TPM) is defined according to WHO criteria as a thyroid tumor smaller than 1-1.5 cm. TPMs are encountered in 0.5-35.6% of autopsies or surgical specimens where carcinoma had been unsuspected. The purpose of the present study was to evaluate patients who had TPMs in terms of clinical findings, histopathological features and immunohistochemical evidence of expression of the tumor suppressor gene p53.

Methods: A total of 44 patients with TPMs less than 1.0 cm in diameter were included in the study. The patients were evaluated clinically and the tumors were evaluated in terms of their histopathological and immunohistochemical features, including expression of p53.

Results: The female/male ratio was 2.8/1, and the median age at time of diagnosis was 49 years (range 20-71 years). The maximum diameter of the smallest focus was 0.1 mm, and that of the largest was 10 mm microscopically. The mean diameter of all tumors was 5.7 mm. There was no correlation between tumor size and age or gender. Of the TPMs, 72% were found in the right lobe, 24% in the left lobe and 4% in the isthmus. Fine-needle aspiration biopsy provided the diagnosis of TPM in only 43.2% of the patients. All patients were treated with surgery, with 20 undergoing conservative surgery, i.e. lobectomy or isthmusectomy, and 24 undergoing total thyroidectomy. Frozen section provided the diagnosis of TPM in only 56.8% of the patients. We found lymphocytic thyroiditis in 13.6% of patients, follicular variants in 11.9%, capsular invasion in 26.8%, lymph node involvement in 11.9%, soft tissue metastases in the neck in 12.1% and multifocality in 31.7%, and none of these were related to age or gender (p > 0.05). No distant metastases were observed during approximately 10 years of follow up. We found p53 positivity in 34.5% of TPM tumors. However, p53 expression was not statistically related to age or gender.

Conclusion: Our findings imply that TPMs may not be entirely innocent since they are associated with signs of poor prognosis such as capsular invasion, multifocal presentation, lymph node involvement and p53 positivity. Therefore, TPMs should be evaluated and followed like classical papillary cancers.

Citing Articles

Thyroid Papillary Microcarcinoma: Etiology, Clinical Manifestations,Diagnosis, Follow-up, Histopathology and Prognosis.

Dideban S, Abdollahi A, Meysamie A, Sedghi S, Shahriari M Iran J Pathol. 2016; 11(1):1-19.

PMID: 26870138 PMC: 4749190.

References
1.
HAZARD J . Small papillary carcinoma of the thyroid. A study with special reference to so-called nonencapsulated sclerosing tumor. Lab Invest. 1960; 9:86-97. View

2.
Jancic-Zguricas M, Jankovic R . Occult papillary carcinoma of the thyroid gland revealed by cancer pericarditis. Pathol Res Pract. 1986; 181(6):761-6. DOI: 10.1016/S0344-0338(86)80053-X. View

3.
Fagin J . Tumor suppressor genes in human thyroid neoplasms: p53 mutations are associated undifferentiated thyroid cancers. J Endocrinol Invest. 1995; 18(2):140-2. DOI: 10.1007/BF03349723. View

4.
Pelizzo M, Piotto A, Rubello D, Casara D, Fassina A, Busnardo B . High prevalence of occult papillary thyroid carcinoma in a surgical series for benign thyroid disease. Tumori. 1990; 76(3):255-7. DOI: 10.1177/030089169007600309. View

5.
HIRABAYASHI R, Lindsay S . THE RELATION OF THYROID CARCINOMA AND CHRONIC THYROIDITIS. Surg Gynecol Obstet. 1965; 121:243-52. View